01/09/2015 18:24:14 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
09/01/20159:00AMBWNew Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. “IMPROVE-IT presents us with the... More...>>
08/28/20154:00PMDJNFDA: Some Diabetes Drugs Can Cause Joint Pain
The U.S. Food and Drug Administration said in a safety alert Friday some widely used treatments for Type 2 diabetes can cause severe and disabling joint pain, raising concerns for a big-selling class of drugs. The FDA alert applies to a category of pills known as DPP-IV inhibitors, which include Merck & Co.'s... More...>>
08/20/20158:30AMBWNew Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe & simvastatin) & the TECOS Cardiovascular Safety Tria...
Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial... More...>>
08/18/20151:17PMBWMerck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
Patients Should Visually Examine Bottle Caps for Cracks and if Cracks are Found, Ensure the Bottles are Stored Out of the Reach of Children Replacement Caps for Patients Are Available Medication Within the Bottles Is Not Affected; Patients May Continue to Take Their Medicine as Prescribed Merck (NYSE: MRK), known as MSD... More...>>
08/18/20158:00AMBWFDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, fo...
Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA... More...>>
08/14/20158:00AMPRNUSCelebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabete...
Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal Chef Leticia Visits the ADA's Feria de Salud in New York City on August 15 with Desafiando La Diabetes: Logra Tus Metas Program PR Newswire KENILWORTH, N.J., Aug. 14, 2015... More...>>
08/13/20158:00AMBWMerck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
Clinical Trials to Evaluate Merck’s KEYTRUDA® (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types Merck (NYSE:MRK), known as MSD outside the United States and Canada, and The University of Texas MD Anderson Cancer Center today announced that they have entered into a strategic... More...>>
07/31/20157:27PMDJNWHO Says Ebola Vaccine Effective in African Trial -- Update
By Thomas M. Burton And Peter Loftus European researchers said an experimental Ebola vaccine tested in West Africa might be highly effective in protecting people from the deadly virus, raising the possibility that it could be used to prevent future epidemics. The vaccine, from Merck & Co. and NewLink Genetics Corp... More...>>
07/31/20153:16PMDJNWHO Says Ebola Vaccine Effective in African Trial -- Update
By Thomas M. Burton And Peter Loftus European researchers said on Friday that an experimental Ebola vaccine tested in Guinea might be effective in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink... More...>>
07/31/20159:00AMDJNWHO Says Ebola Vaccine Effective in African Trial
European researchers said Friday that an experimental Ebola vaccine tested in Guinea "might be effective" in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink Genetics Corp. and dubbed VSV-ZEBOV... More...>>
07/31/20159:00AMDJNWHO Says Ebola Vaccine Effective in African Trial -- Update
By Thomas M. Burton and Peter Loftus European researchers said Friday that an experimental Ebola vaccine tested in Guinea "might be effective" in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink... More...>>
07/31/20158:47AMDJNWHO Says Ebola Vaccine Effective in African Trial
By Thomas M. Burton and Peter Loftus European researchers said Friday that an experimental Ebola vaccine tested in Guinea "might be effective" in protecting people from the deadly virus, but behind the scenes, questions have been raised over the way the study was conducted. The vaccine, from Merck & Co. and NewLink... More...>>
07/31/20158:10AMBWIn Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3... More...>>
07/30/20158:00AMPRNUSCelebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabete...
Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal Chef Leticia Visits Fiesta del Sol in Chicago on July 31 with Desafiando La Diabetes: Logra Tus Metas Program PR Newswire KENILWORTH, N.J., July 30, 2015 KENILWORTH, N.J... More...>>
07/28/20155:00PMDJNGilead Sales Soar on Hepatitis Drugs
Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected sales of the newer Harvoni. For the year, the company again raised its guidance for net product sales, this time by $1... More...>>
07/28/20154:15PMBWPamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Pamela J. Craig, retired chief financial officer of Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice president for medicine of The Johns Hopkins University and chief executive officer of Johns Hopkins Medicine... More...>>
07/28/201512:26PMDJNMerck Earnings Hurt by Arthritis Drug Knockoffs
By Peter Loftus Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck & Co.'s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years. Merck, which handles Remicade marketing in Europe, said the company's sales of the... More...>>
07/28/20158:23AMDJNMerck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
By Angela Chen Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second... More...>>
07/28/20158:20AMDJNMerck Earnings Top Views Amid Cost Cuts
Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second quarter, hurt... More...>>
07/28/20158:12AMDJNMerck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker
By Angela Chen Merck & Co. agreed to buy a privately held developer of cancer immunotherapies for at least $95 million and raised its per-share earnings guidance for the year after reporting better-than-expected profits for the June quarter amid lower costs. Sales, though, fell a worse-than-expected 11% in the second... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150901 18:24